1-(2-Methoxyethyl)-1-propylhydrazine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-Methoxyethyl)-1-propylhydrazine
• 英文别名: 1-(2-methoxyethyl)-1-propylhydrazine
• 化学式: C₆H₁₆N₂O
• 分子量: 132.2
• InChiKey: PYOZYTRNBYKBQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• HERBICIDALLY ACTIVE SUBSTITUTED PHENYLPYRIMIDINE HYDRAZIDES
  申请人：Bayer Aktiengesellschaft

  公开号：US20220033363A1

  公开（公告）日：2022-02-03

  The invention relates to substituted phenylpyrimidine hydrazides of the general formula (I) and their agrochemically acceptable salts and to their use in the crop protection sector. In formula (I), the substituent R 2 represents a hydrazine group. The substituents R 1 and R 3 to R 7 represent radicals such as hydrogen, halogen, amino, nitro and alkyl.

  本发明涉及一般式(I)的取代苯基嘧啶肼及其农业化学上可接受的盐，以及它们在作物保护领域中的应用。在公式(I)中，取代基R2表示肼基。取代基R1和R3到R7表示氢、卤素、氨基、硝基和烷基等基团。
• TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME
  申请人：Corsair Pharma, Inc.

  公开号：US20150166503A1

  公开（公告）日：2015-06-18

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  式子 I、II、III 和 IV 所代表的化合物包括替前列环素和前列环素类似物的前药。用途包括治疗肺高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定的应用。可以使用经皮应用。
• US20140256730A1
  申请人：——

  公开号：US20140256730A1

  公开（公告）日：2014-09-11
• ANTI-EGFR ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20190153108A1

  公开（公告）日：2019-05-23

  The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
• ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20200147235A1

  公开（公告）日：2020-05-14

  The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.